Calibr-Skaggs Institute initiated a first-in-human trial of a novel switchable CAR-T cell therapy for metastatic breast cancer, combining engineered autologous T cells with an antibody-based molecular switch allowing precise control over T cell activation. This approach addresses longstanding challenges of CAR-T therapy in solid tumors, including tumor microenvironment complexity and safety concerns. Additionally, Lyell Immunopharma's CAR-T asset shows promising clinical responses, despite mixed Wall Street reception, highlighting ongoing efforts to expand CAR-T success beyond hematologic malignancies.